According to Global Cord Blood's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.934275. At the end of 2021 the company had a P/E ratio of 6.29.
Year | P/E ratio | Change |
---|---|---|
2021 | 6.29 | -3.02% |
2020 | 6.48 | -28.79% |
2019 | 9.10 | -59.37% |
2018 | 22.4 | -23.3% |
2017 | 29.2 | -6.97% |
2016 | 31.4 | 0.73% |
2015 | 31.2 | 77.25% |
2014 | 17.6 | 4.62% |
2013 | 16.8 | |
2009 | 566 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() | 24.9 | 2,559.82% | ๐บ๐ธ USA |
![]() | -11.8 | -1,365.81% | ๐บ๐ธ USA |
![]() | -259 | -27,868.59% | ๐บ๐ธ USA |
![]() | 45.1 | 4,722.78% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.